US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced its financial results for the first quarter of 2024.
The conglomerate posted $21.38 billion in total sales, up more than 2% from the same quarter in 2023 and marginally below the $21.4 billion expected by Wall Street analysts, based on a survey of analysts by LSEG.
"Reflects our sharpened focus and the progress in our portfolio and pipeline"Excluding certain items, adjusted earnings per share were $2.71, a 12% rise on a year ago and ahead of the $2.64 anticipated by analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze